The immunostimulatory effect of shRNA-mediated SRA downregulation on DC functionality has also been verified using chaperone vaccine targeting the breast cancer antigen HER-2/Neu, suggesting that the approaches to SRA inhibition may broadly enhance the antitumor potency of synthetic chaperone vaccines in the treatment of multiple disease indications. This evidence concerns the gene ERBB2 and breast carcinoma.